Literature DB >> 21646962

Prediction of serotypes causing invasive pneumococcal disease in unvaccinated and vaccinated populations.

Daniel M Weinberger1, Zitta B Harboe, Stefan Flasche, J Anthony Scott, Marc Lipsitch.   

Abstract

INTRODUCTION: Before the introduction of the heptavalent pneumococcal conjugate vaccine (Prevnar-7), the relative prevalence of serotypes of Streptococcus pneumoniae was fairly stable worldwide. We sought to develop a statistical tool to predict the relative frequency of different serotypes among disease isolates in the pre- and post-Prevnar-7 eras using the limited amount of data that is widely available.
METHODS: We initially used pre-Prevnar-7 carriage prevalence and estimates of invasiveness derived from case-fatality data as predictors for the relative abundance of serotypes causing invasive pneumococcal disease during the pre- and post-Prevnar-7 eras, using negative binomial regression. We fit the model to pre-Prevnar-7 invasive pneumococcal disease data from England and Wales and used these data to (1) evaluate the performance of the model using several datasets and (2) evaluate the utility of the country-specific carriage data. We then fit an alternative model that used polysaccharide structure, a correlate of prevalence that does not require country-specific information and could be useful in determining the postvaccine population structure, as a predictor.
RESULTS: Predictions from the initial model fit data from several pediatric populations in the pre-Prevnar-7 era. After the introduction of Prevnar-7, the model still had a good negative predictive value, though substantial unexplained variation remained. The alternative model had a good negative predictive value but poor positive predictive value. Both models demonstrate that the pneumococcal population follows a somewhat predictable pattern even after vaccination.
CONCLUSIONS: This approach provides a preliminary framework to evaluate the potential patterns and impact of serotypes causing invasive pneumococcal disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21646962      PMCID: PMC3142570          DOI: 10.1097/EDE.0b013e3182087634

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  30 in total

1.  Differences in invasive pneumococcal serotypes.

Authors:  S Obaro
Journal:  Lancet       Date:  2001-06-02       Impact factor: 79.321

2.  Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway.

Authors:  Didrik F Vestrheim; E Arne Høiby; Ingeborg S Aaberge; Dominique A Caugant
Journal:  Clin Vaccine Immunol       Date:  2010-01-27

3.  Continued impact of pneumococcal conjugate vaccine on carriage in young children.

Authors:  Susan S Huang; Virginia L Hinrichsen; Abbie E Stevenson; Sheryl L Rifas-Shiman; Ken Kleinman; Stephen I Pelton; Marc Lipsitch; William P Hanage; Grace M Lee; Jonathan A Finkelstein
Journal:  Pediatrics       Date:  2009-07       Impact factor: 7.124

4.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

Authors:  W P Hausdorff; J Bryant; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

Review 5.  Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis.

Authors:  Daniel M Weinberger; Zitta B Harboe; Elisabeth A M Sanders; Moses Ndiritu; Keith P Klugman; Simon Rückinger; Ron Dagan; Richard Adegbola; Felicity Cutts; Hope L Johnson; Katherine L O'Brien; J Anthony Scott; Marc Lipsitch
Journal:  Clin Infect Dis       Date:  2010-09-15       Impact factor: 9.079

Review 6.  Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children.

Authors:  W P Hausdorff; G Siber; P R Paradiso
Journal:  Lancet       Date:  2001-03-24       Impact factor: 79.321

7.  Invasive pneumococcal disease in Alaskan children: impact of the seven-valent pneumococcal conjugate vaccine and the role of water supply.

Authors:  Jay D Wenger; Tammy Zulz; Dana Bruden; Rosalyn Singleton; Michael G Bruce; Lisa Bulkow; Debbie Parks; Karen Rudolph; Debby Hurlburt; Troy Ritter; Joseph Klejka; Thomas Hennessy
Journal:  Pediatr Infect Dis J       Date:  2010-03       Impact factor: 2.129

8.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.

Authors:  Tamara Pilishvili; Catherine Lexau; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Arthur Reingold; Ann Thomas; William Schaffner; Allen S Craig; Philip J Smith; Bernard W Beall; Cynthia G Whitney; Matthew R Moore
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

Review 9.  Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.

Authors:  Daniel J Isaacman; E David McIntosh; Ralf R Reinert
Journal:  Int J Infect Dis       Date:  2009-08-22       Impact factor: 3.623

10.  Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades.

Authors:  Zitta B Harboe; Thomas L Benfield; Palle Valentiner-Branth; Thomas Hjuler; Lotte Lambertsen; Margit Kaltoft; Karen Krogfelt; Hans Christian Slotved; Jens Jørgen Christensen; Helle B Konradsen
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

View more
  15 in total

Review 1.  Serotype replacement in disease after pneumococcal vaccination.

Authors:  Daniel M Weinberger; Richard Malley; Marc Lipsitch
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

2.  Estimating rates of carriage acquisition and clearance and competitive ability for pneumococcal serotypes in Kenya with a Markov transition model.

Authors:  Marc Lipsitch; Osman Abdullahi; Alexander DʼAmour; Wen Xie; Daniel M Weinberger; Eric Tchetgen Tchetgen; J Anthony G Scott
Journal:  Epidemiology       Date:  2012-07       Impact factor: 4.822

3.  Using pneumococcal carriage data to monitor postvaccination changes in invasive disease.

Authors:  Daniel M Weinberger; Dana T Bruden; Lindsay R Grant; Marc Lipsitch; Katherine L O'Brien; Stephen I Pelton; Elisabeth A M Sanders; Daniel R Feikin
Journal:  Am J Epidemiol       Date:  2013-09-07       Impact factor: 4.897

4.  Serotype-specific effect of influenza on adult invasive pneumococcal pneumonia.

Authors:  Daniel M Weinberger; Zitta B Harboe; Cécile Viboud; Tyra G Krause; Mark Miller; Kåre Mølbak; Helle B Konradsen
Journal:  J Infect Dis       Date:  2013-07-30       Impact factor: 5.226

5.  Impact of the 2009 influenza pandemic on pneumococcal pneumonia hospitalizations in the United States.

Authors:  Daniel M Weinberger; Lone Simonsen; Richard Jordan; Claudia Steiner; Mark Miller; Cécile Viboud
Journal:  J Infect Dis       Date:  2011-12-07       Impact factor: 5.226

6.  Relating Pneumococcal Carriage Among Children to Disease Rates Among Adults Before and After the Introduction of Conjugate Vaccines.

Authors:  Daniel M Weinberger; Lindsay R Grant; Robert C Weatherholtz; Joshua L Warren; Katherine L O'Brien; Laura L Hammitt
Journal:  Am J Epidemiol       Date:  2016-05-02       Impact factor: 4.897

7.  Rates of acquisition and clearance of pneumococcal serotypes in the nasopharynges of children in Kilifi District, Kenya.

Authors:  Osman Abdullahi; Angela Karani; Caroline C Tigoi; Daisy Mugo; Stella Kungu; Eva Wanjiru; Jane Jomo; Robert Musyimi; Marc Lipsitch; J Anthony G Scott
Journal:  J Infect Dis       Date:  2012-07-24       Impact factor: 5.226

8.  The serotype distribution among healthy carriers before vaccination is essential for predicting the impact of pneumococcal conjugate vaccine on invasive disease.

Authors:  Stefan Flasche; Olivier Le Polain de Waroux; Katherine L O'Brien; W John Edmunds
Journal:  PLoS Comput Biol       Date:  2015-04-16       Impact factor: 4.475

9.  Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites.

Authors:  Daniel R Feikin; Eunice W Kagucia; Jennifer D Loo; Ruth Link-Gelles; Milo A Puhan; Thomas Cherian; Orin S Levine; Cynthia G Whitney; Katherine L O'Brien; Matthew R Moore
Journal:  PLoS Med       Date:  2013-09-24       Impact factor: 11.069

10.  Optimal serotype compositions for Pneumococcal conjugate vaccination under serotype replacement.

Authors:  Markku Nurhonen; Kari Auranen
Journal:  PLoS Comput Biol       Date:  2014-02-13       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.